An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
Evaluate the reduction in serum phosphorus from baseline to end of study with Sevelamer
carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD)
patients both on haemodialysis and not on dialysis
Secondary Objective:
Evaluate the safety on the basis of adverse events, changes in laboratory values and vital
signs from baseline (Day 0) to Day 56 (End of treatment/ End of Study)